Evaluation of In-Vitro Antimicrobial Activity of Five different Brands of Ciprofloxacin

Abstract

Ciprofloxacin is considered to be one of the most widely used drug in Antibiotic Chemotherapy. In the developed world its use has been minimized with the upcoming of newer generations of Quinolone drugs. But in the developing countries like Bangladesh, Ciprofloxacin is still the most commonly used antibiotic. Therefore in this study we tried to put forward a comparative anti-microbial study of different available brands of Ciprofloxacin drugs. The aim was to evaluate the antibiotic activity of these drugs against available strains of bacteria common in Bangladesh. Five common Ciprofloxacin brands were selected - DFX 500 Tablet (Delta Pharma Limited), Neofloxin 500 Tablet (Beximco Pharmaceuticals Ltd.), Flontin 500 Tablet (Renata Ltd.), Beuflox 500 Tablet (Insepta Pharmaceuticals Ltd.) and Ciprocin 500 Tablet (Square Pharmaceuticals Ltd.) Three concentrations of the drugs were prepared 500 μg/ml, 750 μg/ml and 1000 μg/ml respectively. The different concentrations were used to measure the antimicrobial activity by using disc diffusion method against a blank and a positive control. The positive control is the crude ciprofloxacin supplied by Delta Pharmaceuticals Ltd. The zone of inhibition for each concentration, blank and positive control was measured and compared with other concentrations of all the brands. The zone of inhibitions of each concentrations were compared and it was observed that all the drugs show almost similar zone of inhibitions in each concentrations compared to the standard against most the strains of bacteria. So after carrying out extensive comparison between the different brands it was concluded that all the five brands show activity in the acceptable range. Under antimicrobial susceptibility test, all the five brands have passed the test parameter in comparison with the standard against most of the bacterial strains.